39786-36-2

Usage

Uses

Used in Pharmaceutical Industry:
4-oxo-3,4-dihydro[1]benzofuro[3,2-d]pyrimidin-4(3H)-one is used as a pharmaceutical compound for its potential therapeutic effects. Its unique structure allows it to interact with biological systems, potentially modulating various biological processes and offering new avenues for the treatment of diseases.
Used in Drug Development:
In the field of drug development, 4-oxo-3,4-dihydro[1]benzofuro[3,2-d]pyrimidin-4(3H)-one serves as a lead compound for the design and synthesis of new drugs. Its ability to modulate biological processes makes it a valuable starting point for the development of novel therapeutic agents.
Further research and analysis are required to fully understand the capabilities and potential applications of 4-oxo-3,4-dihydro[1]benzofuro[3,2-d]pyrimidin-4(3H)-one, ensuring its safe and effective use in various industries.

InChI:InChI=1/C10H6N2O2/c13-10-9-8(11-5-12-10)6-3-1-2-4-7(6)14-9/h1-5H,(H,11,12,13)

Upstream product

• 39876-88-5 4-Chlorobenzofuro<3,2-d>pyrimidine 
• 54802-10-7 3-aminobenzofuran-2-carboxamide 
• 77287-34-4 formamide 
• 39786-35-1 ethyl 3-aminobenzofuran-2-carboxylate 
• 122-51-0 orthoformic acid triethyl ester 
• 75746-19-9 3-amino-3,4-dihydro-4-oxobenzofuro<3,2-d>pyrimidine 
• 49679-19-8 4-Aminobenzofuro<3,2-d>pyrimidine 
• 57805-85-3 methyl 3-amino-2-benzofurancarboxylate 
• 611-20-1 salicylonitrile 
• 34844-79-6 methyl 2-(2-cyanophenoxy)ethanoate 
• 75746-17-7 ethyl 3-(ethoxymethylene)amino-2-benzofurancarboxylate 
• 1144105-32-7 4-oxo-3,4-dihydro[1]benzofuro[3,2-d]pyrimidine-2-carboxylic acid 
• 67-56-1 methanol 
• 149-73-5 trimethyl orthoformate 

Downstream Products

• 39876-88-5 4-Chlorobenzofuro<3,2-d>pyrimidine 
• 62208-74-6 4-benzylsulfanyl-benzo[4,5]furo[3,2-d]pyrimidine 

Relevant academic research and scientific papers

Synthesis of ethyl 4-oxo-3,4-dihydro[1]benzofuro[3,2-d]-pyrimidine-2-carboxylate and its derivatives

The synthesis of ethyl 4-oxo-3,4-dihydro[1]benzofuro[3,2-d]pyrimidine-2-carboxylates was developed to modify the benzofuro-[3,2-d]pyrimidine heterocyclic system.

ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT

The present invention concerns a compound of following general formula (I): where: either R is an R1 group and R′ is an -A1-Cy1 group, or R is an -A1-Cy1 group and R′ is an R1 group, R1 particularly being H or (C1-C6)alkyl group;A1 being an —NH— radical or —NH—CH2— radical;Cy1 particularly being a phenyl group,A is a fused (hetero)aromatic ring having 5 to 7 atoms, for use for treating cancer.

Commercial Copper-Catalyzed Aerobic Oxidative Synthesis of Quinazolinones from 2-Aminobenzamide and Methanol

The focus of this study was the development of a new synthetic method for quinazolinones based on the principles of Green Chemistry. Quinazolinones were synthesized from 2-aminobenzamide using methanol as both the C1 source and a green solvent in the presence of base Cs2CO3. Additionally, a commercially available, economical copper complex was used as a catalyst in the reaction. The desired products were achieved in moderate to high yield with up to 99 % isolated yield.

SUBSTITUTED TRICYCLIC PYRIDINE OR PYRIMIDINE VANILLOID RECEPTOR LIGANDS

The present invention relates to substituted tricyclic compounds, which can be used as vanilloid receptor ligands. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by vanilloid receptor-1 (VRl). Also provided herein are pharmaceutical compositions and methods for treating or preventing diseases, conditions and/or disorders modulated by VRl.

Tyrosine kinase inhibitors. 16. 6,5,6-Tricyclic benzothieno[3,2-d]pyrimidines and pyrimido[5,4-b]- and -[4,5- b]indoles as potent inhibitors of the epidermal growth factor receptor tyrosine kinase

Several elaborations of the fundamental anilinopyrimidine pharmacophore have been reported as potent and selective inhibitors of the epidermal growth factor receptor (EGFr) tyrosine kinase. This paper reports on a series of inhibitors whereby some 6,5-bicyclic heteroaromatic systems were fused through their C-2 and C-3 positions to this anilinopyrimidine pharmacophore. Although the resulting tricycles did not produce the enormous potency of some of the (5/6),6,6-bicyclic systems, the best of them had IC50s for the EGFr TK around 1 nM. Investigation of 4-position side chains in the indolopyrimidines confirmed that m-bromoaniline was an optimal substituent for potency. Investigation of substitution within the C-(benzo)ring of benzothienopyrimidines confirmed that introduction of an extra ring can change sharply the effects of substituents when compared to similar bicyclic nuclei, and only two substituents were found which even moderately enhanced inhibitory activity over the parent compound for this series.

Studies in Benzofurans : Part VIII-Synthesis of Some 3-N-aryl-, 3-N-Alkyl- and 3-Amino-3,4-dihydro-4-oxobenzofuropyrimidines

Ethyl 3-amino-2-benzofuran-carboxylate (I) on condensation with ethyl orthoformate and various aromatic amines affords 3-N-aryl-3,4-dihydro-4-oxobenzofuropyrimidines (II).Analogous 3-alkyl and 3-amino compounds have been prepared by the reaction of ethyl 3-(ethoxymethylene)amino-2-benzofurancarboxylate (III) with aliphatic amines and hydrazine hydrate respectively.